We are currently recruiting for our Phase 2 study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
Clinical Trials are Open in the United States and Australia:
NCT06442462 Status: Recruiting
Locations Garden Grove, California, United States, 92845